Pascale Augé

Director/Board Member at

Laboratoire Français du Fractionnement et des Biotechnologies

55 year

44 connections

Finance

Commercial Services

Health Technology

Profile

Pascale Augé currently works at Laboratoire Français du Fractionnement et des Biotechnologies, as Director, INSERM Transfert Initiative SAS, as Director, Linkinvax SA, as Director, and eureKING SA, as Independent Director from 2022.
Dr. Augé also formerly worked at INSERM Transfert SA, as Chairman-Management Board from 2014 to 2025, Ernst & Young Audit SAS (France), as Senior Manager from 2004 to 2011, AB Science SA, as Project Manager from 2003 to 2004, and Novachim SA, as Project Manager.

Pascale Augé active positions

Companies	Position	Start
Laboratoire Français du Fractionnement et des Biotechnologies Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients	Director/Board Member	-
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform	Director/Board Member	-
eureKING SA eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company	Director/Board Member	2022-05-04
INSERM Transfert Initiative SAS INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund	Director/Board Member	-

All active positions of Pascale Augé

Former positions of Pascale Augé

Companies	Position	End
INSERM Transfert SA INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions.	Chief Executive Officer	2025-09-04
Ernst & Young Audit SAS (France) Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services	Corporate Officer/Principal	2010-12-31
AB SCIENCE	Corporate Officer/Principal	2003-12-31
Novachim SA	Corporate Officer/Principal	-

See the detail of Pascale Augé's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Pascale Augé's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
INSERM Transfert SA INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions.	Finance
Ernst & Young Audit SAS (France) Ernst & Young Audit SAS (France) Miscellaneous Commercial ServicesCommercial Services Provides Auditing & Accounting Services	Commercial Services
Laboratoire Français du Fractionnement et des Biotechnologies Laboratoire Français du Fractionnement et des Biotechnologies Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets plasma-derived medicinal products & recombinant proteins for the treatment of patients	Health Technology
INSERM Transfert Initiative SAS INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund	Finance
AB Science SA AB Science SA Pharmaceuticals: OtherHealth Technology Provides biochemical research services	Health Technology
Linkinvax SA Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform	Commercial Services
eureKING SA eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company	Finance
Novachim SA